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A Modular Assembly Platform 
for Rapid Generation of DNA 
Constructs
Elliot H. Akama-Garren1,2,*, Nikhil S. Joshi1,*, Tuomas Tammela1, Gregory P. Chang1, 
Bethany L. Wagner1, Da-Yae Lee1, William M. Rideout III1, Thales Papagiannakopoulos1, 
Wen Xue3 & Tyler Jacks1,2,4
Traditional cloning methods have limitations on the number of DNA fragments that can be 
simultaneously manipulated, which dramatically slows the pace of molecular assembly. Here we 
describe GMAP, a Gibson assembly-based modular assembly platform consisting of a collection of 
promoters and genes, which allows for one-step production of DNA constructs. GMAP facilitates 
rapid assembly of expression and viral constructs using modular genetic components, as well as 
increasingly complicated genetic tools using contextually relevant genomic elements. Our data 
demonstrate the applicability of GMAP toward the validation of synthetic promoters, identification of 
potent RNAi constructs, establishment of inducible lentiviral systems, tumor initiation in genetically 
engineered mouse models, and gene-targeting for the generation of knock-in mice. GMAP represents 
a recombinant DNA technology designed for widespread circulation and easy adaptation for other 
uses, such as synthetic biology, genetic screens, and CRISPR-Cas9.
For decades, molecular cloning has allowed for manipulation of recombinant DNA to assemble DNA 
constructs that are widely used in molecular and synthetic biology. Most commonly, approaches to join 
DNA molecules take advantage of the specificity of restriction endonucleases and PCR to create compati-
ble ends that can be joined using DNA ligase1. These traditional cloning methods rely on the presence of 
restriction sites in both vector and insert, and their prevalence – or lack thereof – can constrain possible 
assemblies, in particular those involving multiple inserts.
Several cloning methods have been developed to overcome these constraints, therefore allowing for 
high-throughput assembly of DNA constructs. Gateway Cloning and other similar site-specific recombi-
nation platforms, such as Creator, Echo, and Univector, rely on recombinase to recombine inserts between 
vectors. However, these methods are limited to “destination” vectors with appropriate recombination 
sequences and only allow cloning of one insert at a time. Moreover, they require proprietary enzyme 
mixes and are expensive relative to traditional cloning methods. New cloning strategies developed within 
the past decade, such as sequence and ligation-independent cloning2,3, Golden Gate Assembly4–6, and 
Gibson Assembly7,8, overcome these sequence requirements and allow for assembly of multiple inserts in 
a given reaction, particularly toward the engineering and study of synthetic biology pathways.
Recently, several frameworks to facilitate modular assembly of DNA constructs have been developed. 
In order to assemble large genetic circuits of multiple transcriptional units, Guye et al. designed a set of 
unique nucleotide sequences that when combined with Gateway Cloning and Gibson Assembly facilitate 
construction of a single construct used for transfection and stable integration in human cells9. A similar 
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approach involves preparation of part libraries via BioBrick Assembly, which are then digested and assem-
bled using Gibson Assembly into destination vectors for bacterial expression or genomic integration into 
mammalian stem cells10. Modular Overlap-Directed Assembly with Linkers (MODAL) relies on a soft-
ware tool to design overlap sequences for Gibson Assembly into yeast and bacterial plasmids11. Several 
Golden Gate based platforms have also been developed for modular scar-benign assembly of plasmids for 
in planta transformation12,13. With these previous advances in synthetic biology circuit design in mind, 
we sought to develop a modular assembly platform using libraries of promoters, genes, and destination 
vectors applicable towards a broader range of techniques common to biomedical research, such as viral 
production and gene targeting.
Here we introduce GMAP (Gibson assembly-based modular assembly platform), which uses Gibson 
Assembly to facilitate the modular assembly of DNA constructs from established collections of pro-
moters, genes, and backbones. GMAP reduces the time frame from the conception of an idea (gene 
knockdown, overexpression, conditional expression) to construct design, assembly, and screening to less 
than three days (Supplementary Fig. S1) and is easily adapted to any destination construct of interest. 
In particular, we establish a common platform for assembly of genetic tools, ranging from expression 
and viral constructs to homologous recombination targeting constructs, in order to address questions of 
increasing biologic complexity.
As the basis for GMAP, we adopted the Gibson assembly method7, which utilizes 30–40 base pair (bp) 
“overlap” sequences between two DNA segments to generate a fusion product (Fig.  1a). Traditionally, 
overlap sequences are fragment-specific and create seamless assembly of fragments. However, in order to 
make GMAP modular, we designed five common overlap sequences (sites #1–5) to designate specified 
positions within the construct (Fig. 1b, Supplementary Fig. S1). These five sequences were used to estab-
lish collections of over 30 promoters and 140 genes (Supplementary Table S1) using the PCR scheme 
outlined in Supplementary Figure S2, and that continue to expand with ongoing experiments. This PCR 
scheme forms the basis of a four fragment design that consists of promoter A (pA):gene A (gA) – pro-
moter B (pB):gene B (gB) or a two fragment design (pC:gB or pA:gC), therefore allowing for modular, 
parts-based assembly of DNA constructs (Fig.  1b). As isothermal assembly and E. coli transformation 
require 30 min, parts can be generated and assembled within a single day.
Each 30 bp overlap sequence encodes a unique restriction enzyme site to facilitate rapid screen-
ing (Fig.  1b). We also designed a series of six sequencing primers that anneal to each 30 bp overlap 
(Supplementary Table S2), allowing for screening via Sanger sequencing. In addition, we optimized reac-
tion parameters and suggest using 200 ng of backbone and incubating for at least 20 min for maximal 
efficiency of assembly of the desired construct (Supplementary Fig. S1). As reaction efficiency decreases 
with increasing fragment number (Supplementary Fig. S1), one must screen at least three bacterial col-
onies for two-fragment (not including backbone) reactions and five for four-fragment reactions to have 
a greater than 99% probability of obtaining at least one correctly assembled colony.
In order to demonstrate the feasibility of using GMAP to create widely applicable expression con-
structs, we first created lentiviral and retroviral constructs (Supplementary Fig. S3). A GMAP-compatible 
pLL3 lentiviral backbone was designed by replacing all components between the Psi element and the 
WPRE sequence with a DNA gene block (Supplementary Table S2) such that linearization with PmeI and 
BsrGI yields a lentiviral backbone with the #1 and #5 sites at the 3′ and 5′ ends, respectively. Similarly, 
in order to generate a GMAP-compatible MSCV retroviral backbone, a DNA gene block (Supplementary 
Table S2) replaced all elements between the Psi element and viral long terminal repeat (LTR) such that 
linearization with PmeI yields sites #2 and #5 at the 3′ and 5′ ends, respectively. This process is eas-
ily adapted to other destination constructs of interest by cloning the appropriate GMAP cassette from 
Supplementary Table S2 into the desired plasmid backbone (see Methods).
We used these GMAP-compatible viral backbones to simultaneously assemble series of retroviral and 
lentiviral constructs with genes and promoters typically used in biomedical research. Using ubiquitous 
and tissue-specific promoters of different strengths, we assembled a series of six retroviral constructs with 
a unique promoter driving expression of GFP. We compared the relative strengths of these promoters by 
transducing a murine lung cancer (KP) cell line or murine 3T6 fibroblast cells with each retrovirus and 
selecting with puromycin (Fig. 1c). GFP expression was then analyzed by flow cytometry, demonstrating 
that CMV in lung cancer cells and CCSP in 3T6 cells were the strongest and weakest promoters respec-
tively, corresponding to a 54.3 ± 5.33-fold difference in median fluorescence intensity (MFI, Fig. 1d).
Another common application of DNA constructs is RNA interference experiments, which are particu-
larly amenable to the modularity and rapidity of GMAP. As such, we used GMAP to assemble a series 
of three lentiviral “sensor” constructs14, each with a unique fluorescent protein that contains a short 
hairpin RNA (shRNA) target sequence in its 3′UTR (Supplementary Fig. S4). We produced such lentivi-
ral constructs with mTagBFP2-AUTR, mKate2-BUTR, or mKusabira-Orange(KO2)-CUTR in the gB position 
and used them to transduce 3TB cells. We developed 3TB cells, a 3T6-derived reporter line engineered 
to become blasticidin resistant after exposure to Cre recombinase (Cre), for easy in vitro validation of 
Cre-expressing constructs (Supplementary Fig. S5). After transduction, sensor 3TB cells were selected 
with hygromycin to establish cell lines stably expressing fluorescent reporters sensitive to shRNA-mediated 
knockdown (Fig. 1e). In order to identify effective shRNAs, we used GMAP to assemble three lentivi-
ral constructs containing doxycycline-inducible hairpins, the reverse tetracycline-transactivator (rtTA3), 
and Cre. We then transfected each sensor 3TB line with an inducible shRNA construct and selected 
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Figure 1. Gibson assembly-based modular assembly platform (GMAP). (A) Promoters, genes, and 
backbones from established GMAP-compatible collections are used in a one step isothermal assembly 
reaction to produce DNA constructs on demand. (B) Schematic of possible orderings of genes and promoters. 
Promoter A (pA) is flanked by sites 1 and 2, promoter B (pB) is flanked by sites 3 and 4, promoter C (pC) 
is flanked by sites 1 and 3, gene A (gA) is flanked by sites 2 and 3, gene B (gB) is flanked by sites 4 and 5, 
and gene C (gC) is flanked by sites 2 and 5. (C) Schematic diagram of experiment using GMAP retroviral 
backbone. Retroviruses expressing GFP driven by different promoters were assembled using GMAP and 
used to transduce murine 3T6 fibroblasts or murine lung cancer (KP) cells. PuroR, puromycin resistance; 
pGK, human phosphoglycerate kinase 1 promoter; CMV, cytomegalovirus immediate-early promoter; EFS, 
elongation factor 1α promoter; SV40, simian virus early 40 promoter; CCSP, clara cell secretory protein 
promoter; UBC, human Ubiquitin C promoter. (D) Bar graph shows flow cytometry measurements of median 
fluorescence intensity (MFI) of GFP from 3T6 and KP cells transduced with GMAP-generated retrovirus. 
Data are representative of at least three independent experiments. (E) GMAP-generated lentiviruses 
expressing mTagBFP2-AUTR (i), mKate2-BUTR (ii), or mKO2-CUTR(iii) sensor cassettes were assembled and 
used to transduce a Cre reporter cell line (3TB). 3TB cells were selected with hygromycin and visualized 
by confocal microscopy. Insets show higher magnification. Scale bar, 100 μ m. (F-H) Histograms from 3TB 
cells expressing mTagBFP2-AUTR (F), mKate2-BUTR (G), or mKO2-CUTR (H) transfected with three inducible 
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with blasticidin (Supplementary Fig. S6). Upon treatment with doxycycline, cells inducibly expressed 
shRNA and knockdown of the endogenous fluorescent protein was assessed by flow cytometry, identify-
ing shRNA “C” as the most potent shRNA (Fig. 1f–h). These results demonstrate the ability of GMAP to 
rapidly assemble and functionally test in vitro retroviral and lentiviral constructs using standard genetic 
components such as synthetic promoters, tetracycline response elements, and shRNAs.
The simplicity and speed of GMAP allows one to assemble not only prototypical expression con-
structs, but also constructs of increasing genetic complexity and biological relevance. In order to demon-
strate the benefit of GMAP’s modularity and non-reliance on unique restriction sites, we used GMAP 
to assess hypoxia in a genetically engineered mouse model of non-small cell lung cancer (NSCLC) 
using an advanced hypoxia response element (HRE):GFP reporter cassette15. Using GMAP we gener-
ated a HRE:GFP-pGK:Cre lentivirus, which was delivered intratracheally to K-rasLSL−G12D/+;p53fl/fl mice16, 
resulting in the development of lung adenocarcinoma. Thirty weeks after tumor induction mice were 
injected with pimonidazole prior to sacrifice, which allowed us to objectively visualize areas of hypoxia 
using immunohistochemistry for pimonidazole adducts that form in hypoxic regions of the tumor. 
Immunohistochemistry revealed that GFP expression co-localized with areas of pimonidazole staining 
(Fig.  2a), demonstrating the accuracy of the HRE:GFP reporter lentivirus and its potential application 
to visualize intratumoral hypoxia, in concordance with previously published data using tumor xeno-
grafts17–19. These data demonstrate just one of many potential in vivo applications of GMAP, which allows 
for easy assembly of lentiviral constructs expressing biologically relevant sequences of unlimited com-
plexity. For example, the modular ability of GMAP enables high throughput production of constructs 
expressing components of the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 
system20, providing a simple method to study genome editing and to perform genetic screens21,22.
Beyond biologically relevant expression constructs, GMAP facilitates high-throughput creation of novel 
genetic tools with greater ease and speed than traditional cloning methods. One such tool is homologous 
recombination constructions designed to mediate targeted genome modification and generate knock-in 
animals23,24. In order to facilitate rapid generation of knock-in animals, we created a GMAP-compatible 
backbone containing Rosa26 homology arms (R26TV), designed to target a CAG-driven loxP-stop-loxP 
(LSL) cassette into the Rosa26 locus (Supplementary Fig. S3), such that sequences inserted via GMAP are 
expressed following exposure to Cre. Using GMAP, we assembled a R26TV LSL construct driving expres-
sion of the tetracycline transrepressor (tTR) from Escherichia coli Tn10 fused to the KRAB domain of 
human Kox1 (tTR-KRAB) linked via a P2A peptide to rtTA3 linked via a degenerate P2A peptide to lucif-
erase. We first validated the tight regulation of tetracycline-response elements by tTR-KRAB-rtTA3-Luc 
(TRL) in vitro by generating a KP-derived cell line engineered to inducibly express CloverCP (VerdeGo). 
VerdeGo cells were transduced using a GMAP-generated lentivirus encoding the full TRL sequence and 
shown to express CloverCP in a doxycycline-dependent manner (Fig. 2c,d). Following in vitro validation, 
C57BL/6J-Tyr c−2J embryonic stem (ES) cells were electroporated with R26TV-LSL-TRL and five clones 
were generated, one of which was positive for Rosa26 integration by PCR screening and Southern analy-
sis (Fig. 2f, Supplementary Fig. S7). These targeted ES cells report Cre recombination via both luciferase 
(Fig. 2g, Supplementary Fig. S7) and doxycycline-inducible expression when combined with a pTRE:iR-
FP670-EFS:Cre-2A-GFP lentivirus generated by GMAP (Fig.  2h, Supplementary Fig. S7). These results 
demonstrate the versatility of GMAP to create genetic tools of increasing complexity, in particular toward 
the rapid validation and generation of knock-in mice.
GMAP provides a platform to address questions of increasing biologic complexity using genetic 
tools, ranging from commonplace expression constructs using simple synthetic elements to homolo-
gous recombination constructs using complex genomic sequences. Additionally, the establishment and 
continuous expansion of a GMAP-compatible collection of promoters, genes, and backbones provides a 
system for the rapid translation of an idea from in vitro testing using retrovirus, to in vivo testing using 
lentivirus, and finally to generation of knock-in mice using Rosa26 homologous recombination targeting 
constructs. We have designed GMAP to be easily and inexpensively adaptable for the creation of com-
patible backbones as well as promoter and gene collections. Recent advances in the fields of synthetic 
biology and genetics, particularly the widespread use of CRISPR-Cas925, rely on the ease of construction 
of increasingly more complicated DNA constructs. As genomics and systems biology lead to the iden-
tification of novel genes and pathways of interest, efficient assembly of DNA constructs to interrogate 
these genes and pathways will become increasingly important. Together with its adaptability for various 
applications and for use by other investigators, GMAP provides a modular assembly platform that sim-
plifies and accelerates this discovery process.
hairpin constructs targeting the A, B, or C 3’UTRs assembled using GMAP. After transfection 3TB cells were 
selected with blasticidin, treated with doxycycline, and knockdown was assessed by flow cytometry analysis 
on GFP+ cells. Grey histograms represent cells lines transfected with an inducible shRNA targeting luciferase. 
Data are representative of at least three independent experiments.
www.nature.com/scientificreports/
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Figure 2. In vivo applications of GMAP using lentiviral and Rosa26 targeting constructs. (A) K-rasLSL−
G12D/+;p53fl/fl mice were infected with GMAP-generated hypoxia response element (HRE):GFP-pGK:Cre 
or pGK:Cre lentivirus. After 30 weeks tumors were assessed for GFP expression, hypoxia as determined 
by pimonidazole staining, and hematoxylin and eosin (H&E). Insets show higher magnification. Data 
are representative of at least three independent experiments. Scale bar, 200 μ m. (B) Column scatter plot 
shows quantification of immunohistochemistry shown in (A). Data are presented as fraction of tumor 
area that expressed GFP or pimonidazole staining. NS, p > 0.05; ***p = 5.82 × 10−12. (C) FACS histogram 
of KP cells engineered to express CloverCP in the presence of doxycycline and rtTA (VerdeGo) that 
were transduced with a GMAP-generated pGK:tTR-KRAB-rtTA3-Luc (TRL)-EFS:iRFP670 lentivirus and 
treated with media (grey histogram) or doxycycline (green line). Data are representative of at least three 
independent replicates. (D) Bar graph shows quantification of flow cytometry shown in (C). NS, p > 0.05; 
**p = 7.68 × 10−4; ***p = 2.46 × 10−4. (E) Map of a GMAP-generated Rosa26 targeting vector (R26TV) 
and scheme for knock-in of a Cre-dependent tTR-KRAB-rtTA3-Luc construct into the Rosa26 locus. LSL, 
loxP-Stop-loxP; NeoR, neomycin resistance; bGH polyA, bovine growth hormone polyadenylation signal; 
www.nature.com/scientificreports/
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Methods
Oligonucleotide design. We designed five 30 bp overlap sequences to flank our four possible frag-
ments in each construct. The sequences are: site #1, GATCAGTGTGAGGGAGTGTAAAGCTGGTTT; 
site #2, CTAACTCGAACGCTAGCTGTGCGATCGTTT; site #3, AAACCGCTGTTCCTAGGAATCCC 
GAGGCCT; site #4, GACCCGACATTAGCGCTACAGCTTAAGCGG; site #5, AAACGTTGTTGTTT 
GGGGTTGAATTACTCT. In order to amplify compatible genes and promoters, primers were designed 
to include the appropriate sites as primer overhangs in addition to standard PCR homology sequences. 
Primers were purchased from Integrated DNA Technologies (IDT) unmodified with standard desalting; 
sequences are available in Supplementary Table S3.
Preparation of promoter and gene collections. Promoters were named pA, pB, or pC and genes 
were named gA, gB, or gC to designate their location in the four fragment scheme (Fig. 1b). To produce 
pA, F1 and R2 primers are used; to produce pB, F3 and R4 primers are used; to produce pC, F1 and R4 
primers are used. To produce gA, F2 and R3 primers are used; to produce gB, F4 and R5 primers are 
used; to produce gC, F2 and R5 primers are used. Promoters and genes were amplified using PrimeSTAR 
HS (Takara) with an annealing temperature of 62 °C and extension lengths of 1 min/kb. PCR products 
were extracted from agarose gels after electrophoresis using the QIAquick Gel Extraction kit (Qiagen) 
or purified using the QIAquick PCR Purification kit (Qiagen) according to the manufacturer’s protocol. 
Promoters and genes were then adjusted to 57 nM with Tris-EDTA buffer (pH = 8.0), entered into the 
online database (Supplementary Table S1), and stored at − 20 °C. We have generated GMAP-compatible 
TOPO constructs, which may serve as templates for investigators to amplify their own GMAP promoter 
and gene collections using primers from Supplementary Table S3. All TOPO constructs containing the 
promoters and genes described herein have been deposited in Addgene.
Preparation of backbones. Compatible backbones were created by designing gene blocks (gBlocks) 
from IDT (Supplementary Table S2) to clone into viral or R26TV constructs such that digestion and gel 
purification would yield linearized backbones with sites #1 and 5 or sites #2 and 5 terminal. The retro-
viral backbone (RV 2-5) was created by cloning “RV 2–5 gBlock” into MSCV linearized with BglII and 
ClaI using Gibson Assembly such that digestion with PmeI followed by PCR purification yields a GMAP 
compatible backbone. The lentiviral backbone (LV 1–5) was created by cloning “LV 1–5 gBlock” into 
pLL3 linearized with XmaI and AscI using Gibson Assembly such that digestion with PmeI and BsrGI 
eliminates the 469 bp spacer sequence between sites #1 and 5. The CAG-driven R26TV LSL backbone 
(R26TV CAG LSL 2−5) was created by cloning “Rosa26 LSL 2–5 gBlock” into a R26TV LSL-GFP plas-
mid (Addgene plasmid 16103) linearized with Asc and XmaI such that digestion with PmeI eliminates 
a 389 bp spacer sequence between sites #2 and 5. This targeting construct has 5′ and 3′ homologous 
arms of 1.1 and 4.3 kb, respectively. TOPO backbones were created by linearizing PCR-BluntII TOPO 
with BamHI and cloning in “TOPO 1-4 gBlock” or “TOPO 2-5 gBlock” using Gibson Assembly such 
that digestion with PmeI and NheI eliminates a 361 bp spacer sequence between sites #1 and 4, or diges-
tion with PmeI eliminates a 389 bp spacer sequence between sites #2 and 5, respectively. Following gel 
extraction, linearized backbones were adjusted to 57nM with Tris-EDTA buffer (pH = 8.0). All GMAP 
backbones described herein have been deposited in Addgene.
One-step isothermal assembly. DNA constructs were assembled from our collections of promot-
ers, genes, and backbones (Supplementary Table S1) using Gibson Assembly7. Briefly, 5X isothermal 
assembly reaction buffer was prepared by combining 3 mL of 1 M Tris-HCl (pH = 7.5), 300 μ L of 1 M 
MgCl2, 600 μ L of 10 mM dNTPs, 300 μ L of 1M DTT, 1.5 g of PEG-8000, 20 mg of NAD, and water up 
to 6 mL, aliquoted and stored at − 20 °C. Isothermal master mix was prepared by combining 320 μ L of 
5X isothermal assembly reaction buffer, 1.2 μ L of T5 exonuclease (NEB), 20 μ L of Phusion polymer-
ase (NEB), 160 μ L of Taq ligase (NEB), and 700 μ L of water, aliquoted and stored at − 20 °C. For each 
individual reaction, 15 μ L of isothermal master mix was added to 5 μ L of promoter, genes, and inserts 
DTA, diphtheria toxin fragment A. Relevant primer binding sites (black half arrow) for PCR screening 
and restriction sites and probe (grey line) for Southern analysis are shown. (F) Southern analysis of ES cell 
DNA. C57BL/6J-Tyrc-2J ES cells were electroporated with AsiSI-linearized R26TV and subclone genomic DNA 
was digested with BamHI and probed, yielding a 5.8 kb product for the wild type Rosa26 locus and a 4.8 kb 
product for the targeted Rosa26 allele. A1-D1, clone number; + , positive control; arrow, targeted product. 
(G) Bioluminescence imaging of C57BL/6J-Tyrc-2J or R26LSL-TRL (clone D1) ES cells transduced with increasing 
multiplicity of infection (MOI) CMV-Cre adenovirus (Ad-Cre). Data are representative of at least three 
independent replicates. (H) Plot shows flow cytometry measurement of iRFP670 expression in C57BL/6J-
Tyrc-2J or R26LSL-TRL ES cells transduced with a GMAP-generated tetracycline response element promoter 
(pTRE):iRFP670-EFS:Cre-2A-GFP lentivirus and treated with doxycycline. Data are representative of at least 
three independent replicates. **p = 3.71 × 10−3; ***p = 6.51 × 10−4; ****p = 3.60 × 10−5.
www.nature.com/scientificreports/
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(5.7 × 10−2 pmol each) and incubated at 50 °C for 20 min (Supplementary Figure S1). This reaction mix 
was then transformed into competent bacteria, and screened using XmaI, NheI, AvrII, AfeI, or AscI.
Establishment of 3TB cell line. The sequence for blasticidin resistance was PCR amplified and 
cloned using Gibson Assembly into a pcDNA5 donor vector such that it is inverted and flanked by 
two sets of incompatible loxP sequences. The inverted and floxed blasticidin resistance sequence was 
then PCR amplified and cloned using Gibson Assembly into a MSCV pGK-PuromycinR vector such 
that inverted blasticidin resistance expression is driven by the retroviral LTR (FFiBlast MSCV Puro). 
Murine 3T6 fibroblasts were transduced using FFiBlast MSCV Puro, selected in 5 μ g/mL puromycin (Life 
Technologies), single cell cloned, and screened using CMV-Cre adenovirus (Ad-Cre). A Cre-responsive 
clone was expanded for in vitro use (3TB).
Cell culture. Human embryonic kidney cells (HEK-293FS), 3TB cells, and KP cells were cultured in 
DMEM (Corning) supplemented with L-glutamine (2 mM), penicillin (100 U/mL), streptomyocin (100 μ g/
mL), and 10% fetal calf serum (FCS; Gibco) at 37 °C in a 5% CO2 humidified atmosphere. Embryonic 
stem (ES) cells were cultured on primary irradiated mouse embryonic fibroblasts in Knockout DMEM 
(Life Technologies) supplemented with β -mercaptoethanol (100 μ M), L-glutamine (2 mM), penicillin 
(100 U/mL), streptomycin (100 μ g/mL), 1X Non-essential Amino Acids (Sigma), leukemia inhibitory fac-
tor (200 pg/mL; Amsbio), CHIR99021 (3 μ M; P212121) and PD0325901 (1 μ M; Selleck Chemicals), and 
15% FCS at 37° in a 5% CO2 humidified atmosphere. Following transduction of 3TB or KP cells with len-
tivirus or retrovirus, 5 μ g/mL puromycin (Life Technologies), 400 μ g/mL hygromycin (EMD Millipore), 
400 μ g/mL zeocin (Life Technologies), or 20 μ g/mL blasticidin (Invitrogen) selection was applied, as 
appropriate. To induce shRNA expression, transfected 3TB cells were treated with 5 μ g/mL doxycycline 
(Sigma) for 48 hr. To induce CloverCP expression, VerdeGo cells were treated with 1 μ g/mL doxycycline 
for 7 days. To induce iRFP670 expression, ES cells were treated with varying doxycycline for 3 days.
Viral production and transduction. For transfection experiments, HEK-293FS cells were trans-
fected using TransIT-LT1 (Mirus Bio) in Opti-MEM (Life Technologies) and 3TB cells were transfected 
using Attractene Transfection Reagent (Qiagen) in Opti-MEM. Retrovirus was produced by transfection 
of 5 × 105 HEK-293FS cells with 1 μ g Phoenix-E and 2μ g retroviral construct and supernatant filtration 
through 0.45 μ m syringe filters (VWR). Lentivirus was produced by transfection of HEK-293FS cells with 
Δ 8.2 (gag/pol), CMV-VSV-G, and lentiviral construct as previously described16.
Rosa26 homologous recombination. For targeting experiments, 40 μ g of R26TV was linearized 
with AsiSI (NEB) and electroporated into 1 × 106 C57BL/6J-Tyr c−2J ES cells with a single pulse of 600V, 
25 μ F. After 24 hr cells were selected with 300 μ g/mL G418 (Life Technologies) for 7 days, followed by 
isolation of five subclones.
Confocal microscopy. Cells were plated on Cover Glass Circles (Fisher) at 250 cells/mm2. After 24 h 
cells were washed with PBS and nuclear staining was accomplished using DAPI (5 μ g/mL) or TO-PRO-1 
(Invitrogen) prior to fixation with 1% paraformaldehyde (PFA, Electron Microscopy Sciences) and 
mounting with Vectashield Mounting Medium (Vector Laboratories). Images were acquired on an 
Olympus FV1200 Laser Scanning Confocal Microscope and analyzed with ImageJ (NIH, Bethesda, MD).
Flow cytometry. Flow cytometry data were collected after 3–7 days of selection. Cells were trypsin-
ized and fixed with Cytofix/Cytoperm (BD) and read on a BD LSR II HTS-2. Data was analyzed using 
Flowjo software (Tree Star).
Mice. All animal studies described in this study were performed in accordance with protocols approved 
by the MIT Institutional Animal Care and Use Committee. All animals were maintained on a mixed 
C57BL/6J × 129SvJ genetic background. K-rasLSL−G12D/+; p53fl/fl mice have been previously described26,27. 
Mice were infected intratracheally with 1 × 104 transforming units lentivirus as described16 and exam-
ined after 30 weeks.
Immunohistochemistry. To visualize hypoxic areas by immunohistochemistry, a commercially avail-
able hypoxyprobe kit (Hypoxyprobe™ -1 Omni) was utilized. Pimonidazole hydrochloride was injected 
intraperitoneally into tumor-bearing mice at a dose of 60 mg/kg body weight 1 h before euthanasia. Lungs 
were perfused through the trachea with 4% PFA, fixed overnight, transferred to 70% ethanol and sub-
sequently embedded in paraffin. Sections were cut at a thickness of 4 μ m and stained with hematoxylin 
and eosin for pathological examination. Slides were antigen retrieved using Thermo citrate buffer, pH 
6.0 and treated with Peroxidase and Alkaline Phosphatase Block (Dako), normal horse serum (Vector 
Labs), primary antibody, and anti-rabbit (Vector Labs) HRP-polymer. The slides were developed with 
ImmPACT DAB Peroxidase (Vector Labs), counterstained with haematoxylin in a Thermo Gemini 
stainer and coverslips added using the Thermo Consul cover slipper. The following antibodies were used 
for IHC: anti-TTF1 / Nkx2.1 (Epitomics, EP1584Y, 1:1,200), anti-GFP (Cell Signaling, 2956, 1:100), and 
www.nature.com/scientificreports/
8Scientific RepoRts | 6:16836 | DOI: 10.1038/srep16836
anti-Pimonidazole (Hypoxyprobe, 1:500). All images were obtained using a Nikon 80i microscope with 
a DS-U3 camera and NIS-elements software.
Southern analysis. Genomic DNA was isolated from ES cell subclones as previously described28 and 
digested with BamHI (NEB) overnight. Digestions were electrophoresed on 0.7% agarose gels and blot-
ted to Amersham Hybond-N+ nylon membranes (GE Healthcare). 32P-labeled 5′ probe was synthesized 
using BW13 (AGACAAAACCCAGAGCCCAGAGC) and BW14 (TTGGGCCTAACTCGAGTCTCGCT) 
and applied in Church buffer29.
PCR analysis. Primers to detect the R26LSL-TRL allele (R26For, GAAGAGGCTGTGCTTTGGG; 
R26Rev, ACCACTGGAAAGACCGCGAAGAG) were designed by the Primer3 program (www.http://
biotools.umassmed.edu/bioapps/primer3_www.cgi). PCR amplifications were performed on 50 ng of 
genomic DNA using Green Taq DNA Polymerase (GeneScript). Targeted Rosa26 allele yields a 1302 bp 
product and wild type Rosa26 yields no product.
Luciferase analysis. ES cells (1 × 104) were seed in each well of a 48-well and transduced with vary-
ing Ad-Cre. After 3 days, 150 μ g/mL D-Luciferin (Perkin Elmer) was applied and cells were imaged using 
the IVIS Spectrum Imaging System (Perkin Elmer). Cells were then washed with PBS, lysed with 30 μ L 
Cell Culture Lysis Reagent (Promega), and supernatant was incubated with Luciferase Assay Reagent 
(Promega). Luminescence was measured using a Tecan Infinite M200 PRO Plate Reader.
Crystal violet stain. Transduced 3T6 fibroblast subclones (2 × 104) were seed in a 24-well and trans-
duced with Ad-Cre (MOI= 100). After 48 h, 20 μ g/mL blasticidin was applied and after 4 days cells were 
washed with PBS and fixed with 1% PFA. Cells were then washed with PBS, stained with 0.5% crystal 
violet in 2.5% methanol for 30 min, and rinsed in dH2O.
Statistical analysis. Statistical analysis was performed using unpaired two-tailed Student t tests in 
Prism 5 (Graphpad Software). Data are presented as mean ± standard error of the mean.
References
1. Lodish, H. et al. Molecular Cell Biology. (W. H. Freeman, 2000).
2. Li, M. Z. & Elledge, S. J. Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. Nat. Methods 
4, 251–256 (2007).
3. Aslanidis, C. & de Jong, P. J. Ligation-independent cloning of PCR products (LIC-PCR). Nucleic Acids Res. 18, 6069–6074 (1990).
4. Scior, A., Preissler, S., Koch, M. & Deuerling, E. Directed PCR-free engineering of highly repetitive DNA sequences. BMC 
Biotechnol. 11, 87 (2011).
5. Werner, S., Engler, C., Weber, E., Gruetzner, R. & Marillonnet, S. Fast track assembly of multigene constructs using Golden Gate 
cloning and the MoClo system. Bioeng. Bugs 3, 38–43 (2012).
6. Weber, E., Engler, C., Gruetzner, R., Werner, S. & Marillonnet, S. A Modular Cloning System for Standardized Assembly of 
Multigene Constructs. PLoS ONE 6, e16765 (2011).
7. Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343–345 (2009).
8. Gibson, D. G., Smith, H. O., Iii, C. A. H., Venter, J. C. & Merryman, C. Chemical synthesis of the mouse mitochondrial genome. 
Nat. Methods 7, 901–903 (2010).
9. Guye, P., Li, Y., Wroblewska, L., Duportet, X. & Weiss, R. Rapid, modular and reliable construction of complex mammalian gene 
circuits. Nucleic Acids Res. 41, e156–e156 (2013).
10. Torella, J. P. et al. Rapid construction of insulated genetic circuits via synthetic sequence-guided isothermal assembly. Nucleic 
Acids Res. 42, 681–689 (2014).
11. Casini, A. et al. One-pot DNA construction for synthetic biology: the Modular Overlap-Directed Assembly with Linkers 
(MODAL) strategy. Nucleic Acids Res. 42, e7–e7 (2014).
12. Binder, A. et al. A Modular Plasmid Assembly Kit for Multigene Expression, Gene Silencing and Silencing Rescue in Plants. PLoS 
ONE 9, e88218 (2014).
13. Sarrion-Perdigones, A. et al. GoldenBraid 2.0: A Comprehensive DNA Assembly Framework for Plant Synthetic Biology. Plant 
Physiol. 162, 1618–1631 (2013).
14. Fellmann, C. et al. Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay. Mol. Cell 41, 
733–746 (2011).
15. Semenza, G. L. et al. Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters 
Contain Essential Binding Sites for Hypoxia-inducible Factor 1. J. Biol. Chem. 271, 32529–32537 (1996).
16. DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre 
recombinase. Nat. Protoc. 4, 1064–1072 (2009).
17. Liu, J. et al. Real-time Imaging of Hypoxia-inducible Factor-1 Activity in Tumor Xenografts. J. Radiat. Res. (Tokyo) 46, 93–102 
(2005).
18. Carlin, S. et al. In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression. Nucl. Med. Biol. 
36, 821–831 (2009).
19. Dang, D. T. et al. Hypoxia-Inducible Factor-1α Promotes Nonhypoxia-Mediated Proliferation in Colon Cancer Cells and 
Xenografts. Cancer Res. 66, 1684–1693 (2006).
20. Sánchez-Rivera, F. J. et al. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516, 
428–431 (2014).
21. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic Screens in Human Cells Using the CRISPR-Cas9 System. Science 343, 
80–84 (2014).
22. Shalem, O. et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 343, 84–87 (2014).
www.nature.com/scientificreports/
9Scientific RepoRts | 6:16836 | DOI: 10.1038/srep16836
23. Srinivas, S. et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 
1, 4 (2001).
24. Xiao, C. et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131, 146–159 (2007).
25. Hsu, P. D., Lander, E. S. & Zhang, F. Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell 157, 
1262–1278 (2014).
26. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes 
Dev. 15, 3243–3248 (2001).
27. Jackson, E. L. et al. The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer. Cancer Res. 65, 10280–10288 
(2005).
28. Laird, P. W. et al. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 19, 4293 (1991).
29. Church, G. M. & Gilbert, W. Genomic sequencing. Proc. Natl. Acad. Sci. 81, 1991–1995 (1984).
Acknowledgements
We thank F. Sanchez-Rivera and N. Dimitrova for critical reading of the manuscript. We also thank 
K. Thai and M. Taipale for cloning the HRE:GFP-pGK:Cre lentiviral construct, M. Bauer for technical 
assistance using the IVIS Spectrum Imaging System, P. Cabeceiras for single cell cloning of the VerdeGo 
cell line, and L. Schmidt for luciferase assay reagents. This work was supported by the Howard Hughes 
Medical Institute, MIT Amgen-UROP Program (E.A.G.) and the MIT Peter J. Eloranta Fellowship 
(E.A.G.). T.J. is a Howard Hughes Medical Institute Investigator, the David H. Koch Professor of Biology, 
and a Daniel K. Ludwig Scholar.
Author Contributions
E.A.G. and N.S.J. developed the GMAP system; E.A.G., N.S.J., T.T. and T.P. designed experiments; 
E.A.G., N.S.J., T.T., B.L.W., G.P.C., D.Y.L. and W.M.R. performed research; E.A.G. and N.S.J. analyzed 
data; E.A.G. wrote the paper. W.X. provided conceptual advice and reagents. T.J. oversaw the research. 
All authors read and approved the manuscript for submission.
Additional Information
Accession Codes: The following plasmids were deposited into Addgene: TOPO 2-5, TOPO 1-4, RV 
2-5, LV 1-5, R26TV CAG LSL 2-5, TOPO mTagBFP2, TOPO mKate2, TOPO mKO2, TOPO iRFP670, 
TOPO CloverCP, TOPO HygroR, TOPO ZeoR, TOPO PuroR, TOPO rtTA3-2A-Cre, TOPO tTR-
KRAB-rtTA3-Luc, TOPO Cre-2A-GFP, TOPO EFS, TOPO pGK, TOPO CMV, TOPO CCSP, TOPO 
sv40, TOPO UBC, TOPO pTRE, and TOPO HRE. 3TB cells and VerdeGo cells are available upon 
request.
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Akama-Garren, E. H. et al. A Modular Assembly Platform for Rapid 
Generation of DNA Constructs. Sci. Rep. 6, 16836; doi: 10.1038/srep16836 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The 
images or other third party material in this article are included in the article’s Creative Com-
mons license, unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to reproduce 
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
